| Antimicrobial resistance in ESKAPE pathogens DMP De Oliveira, BM Forde, TJ Kidd, PNA Harris, MA Schembri, ... Clinical microbiology reviews 33 (3), 10.1128/cmr. 00181-19, 2020 | 1298 | 2020 |
| Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a … PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ... Jama 320 (10), 984-994, 2018 | 614 | 2018 |
| The emerging threat of multidrug-resistant Gram-negative bacteria in urology HM Zowawi, PNA Harris, MJ Roberts, PA Tambyah, MA Schembri, ... Nature Reviews Urology 12 (10), 570-584, 2015 | 425 | 2015 |
| β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few … PNA Harris, PA Tambyah, DL Paterson The Lancet Infectious Diseases 15 (4), 475-485, 2015 | 230 | 2015 |
| Colistin resistance: a major breach in our last line of defence DL Paterson, PNA Harris The Lancet Infectious Diseases 16 (2), 132-133, 2016 | 193 | 2016 |
| Health risks of flood disasters DL Paterson, H Wright, PNA Harris Clinical Infectious Diseases 67 (9), 1450-1454, 2018 | 167 | 2018 |
| Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae TM Ng, WX Khong, PNA Harris, PP De, A Chow, PA Tambyah, DC Lye PloS one 11 (4), e0153696, 2016 | 150 | 2016 |
| Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? PNA Harris, JK Ferguson International journal of antimicrobial agents 40 (4), 297-305, 2012 | 148 | 2012 |
| Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches MJ Roberts, HY Bennett, PN Harris, M Holmes, J Grummet, K Naber, ... Urology 104, 11-21, 2017 | 146 | 2017 |
| Treatment of infections by OXA-48-producing Enterobacteriaceae A Stewart, P Harris, A Henderson, D Paterson Antimicrobial agents and chemotherapy 62 (11), 10.1128/aac. 01195-18, 2018 | 138 | 2018 |
| Achromobacter Infections and Treatment Options B Isler, TJ Kidd, AG Stewart, P Harris, DL Paterson Antimicrobial agents and chemotherapy 64 (11), 10.1128/aac. 01025-20, 2020 | 110 | 2020 |
| Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis E Righi, AM Peri, PNA Harris, AM Wailan, M Liborio, SW Lane, ... Journal of Antimicrobial Chemotherapy 72 (3), 668-677, 2017 | 102 | 2017 |
| Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study A Henderson, DL Paterson, MD Chatfield, PA Tambyah, DC Lye, PP De, ... Clinical Infectious Diseases 73 (11), e3842-e3850, 2021 | 100 | 2021 |
| Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline? D Koulenti, A Song, A Ellingboe, MH Abdul-Aziz, P Harris, E Gavey, ... International journal of antimicrobial agents 53 (3), 211-224, 2019 | 90 | 2019 |
| Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic … PNA Harris, JY Wei, AW Shen, AA Abdile, S Paynter, RR Huxley, ... Journal of Antimicrobial Chemotherapy 71 (2), 296-306, 2016 | 84 | 2016 |
| Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp … PNA Harris, AY Peleg, J Iredell, PR Ingram, S Miyakis, AJ Stewardson, ... Trials 16, 1-8, 2015 | 83 | 2015 |
| Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition PNA Harris, JF McNamara, DC Lye, JS Davis, L Bernard, AC Cheng, ... Clinical microbiology and infection 23 (8), 533-541, 2017 | 75 | 2017 |
| Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia … PNA Harris, M Yin, R Jureen, J Chew, J Ali, S Paynter, DL Paterson, ... Antimicrobial resistance and infection control 4, 1-10, 2015 | 75 | 2015 |
| Long-term morbidity and mortality following bloodstream infection: a systematic literature review JF McNamara, E Righi, H Wright, GF Hartel, PNA Harris, DL Paterson Journal of Infection 77 (1), 1-8, 2018 | 73 | 2018 |
| Clinical management of infections caused by Enterobacteriaceae that express extended-spectrum β-lactamase and AmpC enzymes PNA Harris Seminars in respiratory and critical care medicine 36 (01), 056-073, 2015 | 72 | 2015 |
